Long-term complete response of metastatic adrenocortical carcinoma using streptozotocin-based therapy

2026/01/01 by L. Martel-Duguech, Otilia Kimpel, Carmina Fuss +7 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Adrenal and Paraganglionic Tumors #Cancer, Hypoxia, and Metabolism #Cardiac tumors and thrombi

paper · doi:10.1530/eo-25-0047

openalex publication_date 2026/01/01 · openalex created_date 2026/03/20 · openalex updated_date 2026/07/08

Abstract

Summary Metastatic adrenocortical carcinoma in adults carries a very poor prognosis with rare complete response following local and systemic therapies. Combined therapy with etoposide, doxorubicin, cisplatin, and mitotane (EDP-M) provided a better response rate than streptozotocin and mitotane (Sz-M). Here, we report three patients with metastatic adrenocortical carcinoma, two of which were participants in the FIRM-ACT study, who achieved and maintained long-term complete response following Sz-based therapy after disease progression or toxicity with first-line treatments. Learning points

Discussions

• Metastatic ACC has a poor prognosis and complete responses are rare. A new article suggests that streptozotocin & mitotane (or Sz alone) could be a valuable second-line option for advanced ACC after [bsky, 1 points, 0 comments]

Related

• Combination Chemotherapy in Advanced Adrenocortical Carcinoma
• Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials
• Chemo–immunotherapy with cisplatin and nivolumab as second-line approach in metastatic adrenocortical carcinoma
• European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
• Activity and safety of temozolomide in advanced adrenocortical carcinoma patients